LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia. Presbyopia impacts almost two billion people globally and more than 120 million people in the US. LENZ Therapeutics is headquartered in San Diego, California, and is backed by multiple blue-chip venture capital investors.  

LENZ Therapeutics

********* ***** **************, *** **** - *********, **

Specialty Sales Representative, Eye Care - West Palm Beach, FL

District Manager, Sales - Mid-South Region

Specialty Sales Representative, Eye Care - San Diego, CA

Specialty Sales Representative, Eye Care - Honolulu, HI

Staff Accountant (AP/AR)

VP/SVP, Human Resources

LENZ Therapeutics welcomes Apple Decena as our new Senior Accountant. Apple brings a strong background in accounting and has over 8 years of experience in Accounts Receivable and Accounts Payable roles. 

Join us in welcoming Apple to the team!

LENZ Therapeutics welcomes Tori Renfro as Quality Specialist. 

Tori brings several years of experience in quality control and manufacturing within regulated environments. Most recently, she worked as a Quality Control Scientist, focusing on compliance, cross-functional support, and continuous improvement. Tori will be responsible for managing our product complaint process and assisting in batch release.

Join us in welcoming Tori to the team!

 Insider Trading: RA Capital Buys Stock Worth $15M in LENZ Therapeutics - TipRanks.com 

 Lenz Therapeutics, Laboratoires Thea enter license, commercialization agreement 

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference - The Manila Times

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials - Business Wire

 Graphite Bio to Pay Special Dividend Linked to Lenz Therapeutics Merger 

LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision By Investing.com - Investing.com South Africa

LENZ Therapeutics gets fresh set of eyes with $47M ...

Chris Lievens, OD MS PhD, is motivated by an innovative presbyopia treatment that ensures better results for him and his patients. 
 
"As both a practitioner and a presbyope, I'm anticipating the transformative impact a new solution could have on my own life and the lives of my patients."
 
www.EyeAmSelective.com
#presbyopia 

 LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada 

LENZ Therapeutics and Lotus partner for LNZ100 distribution in Asia - World Pharmaceutical Frontiers

LENZ stock touches 52-week high at $31.05 amid market optimism - Investing.com

LENZ Therapeutics welcomes Marianna Rabinovich as our new Manager of Payroll and Equity Administration. Marianna joins us with nearly 20 years of experience in the HR and Payroll field, with the last 6 years exclusively in the biotech industry, including Poseida Therapeutics, Zentalis Inc. and Bionano. 

Join us in welcoming Marianna to the team!

 Geopolitics, rates drag on private equity deals; Israel's high PE ... 

rss_feedRSS News Feed

LENZ Therapeutics inks deal with Lotus for eye treatment - Investing.com

LENZ Therapeutics Merges With Graphite Bio - San Diego Business Journal

San Diego’s Lenz Therapeutics snags $83.5M for once-a-day eye drops to replace near-vision glasses - San Diego Union-Tribune

LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Mark Schaeffer, OD, FAAO believes presbyopia solutions are active and continuously changing. 
 
"The presbyopia market is dynamic. It reflects our patients’ evolving visual needs and their desire for a solution that provides clear vision on their own terms. Vision is dynamic, too—so shouldn’t we consider a solution that mirrors that?"
 
 www.EyeAmSelective.com
 #presbyopia

Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio - Wilson Sonsini

Transcript : LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com

 Graphite Bio stock gains on merger with LENZ Therapeutics 

 LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference 

Investors & Media

 Lenz Therapeutics, Corxel Pharmaceuticals report topline data from JX07001 trial 

Pencils down for Graphite, as gene editing biotech merges into vision-loss-focused Lenz - Fierce Biotech

We are hiring! LENZ Therapeutics is searching for a Sr. Quality Specialist.

This position will support the development, implementation, and maintenance of Quality Systems necessary for the commercial launch and maintenance of ophthalmic combination products.

Other responsibilities for this role include date review and verification, support administration of electronic QMS and Regulatory software(s), product complaint handling and management review program. 

If you are ready to join our team, click link below to apply: https://lnkd.in/gmEr7VXj

LENZ Therapeutics inks exclusive commercialization agreement with Lotus Pharmaceutical - MSN

LENZ Therapeutics Prepares for LNZ100 Launch - TipRanks

LENZ Therapeutics announces positive results from Phase 3 CLARITY trials - Optometry Times

 LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials 

A Sickle Sequel: Matthew Porteus Launches Kamau with Positive Nula-Cell Patient Zero Results - Genetic Engineering & Biotechnology News

 LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights 

LENZ reports positive results from presbyopia treatment trial - Clinical Trials Arena

Geode Capital Management LLC Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia - Stock Titan

LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know - Yahoo Finance

Patent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial Stability - TipRanks

 Lenz Therapeutics Completes Merger With Graphite Bio, Inc. 

 Lenz Therapeutics management to meet with Piper Sandler 

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study - ETHealthWorld

A gene editing biotech’s struggles end with reverse merger - BioPharma Dive

LENZ Therapeutics, Inc.

Will LENZ's Presbyopia Eye Drop Disrupt the Vision Care Market? Commercial Strategy Reveal Coming - Stock Titan

 LENZ Therapeutics, Inc. (LENZ) Files for 13.07M Share Offering by Selling Stockholders 

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by State Street Corp - MarketBeat

Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - Stock Titan

LENZ Therapeutics gets fresh set of eyes with $47M funding to bring eyedrop to market - Fierce Biotech

Behind the Bell: LENZ Therapeutics - Nasdaq

 LENZ Therapeutics to Host Commercial Day on April 15, 2025 

 LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and ... 

 Piper Sandler Starts LENZ Therapeutics Inc (LENZ) at Overweight 

 LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 

View All News

Lenz Therapeutics inks $125M licensing deal with Lotus - Axios

LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch

Corxel, Lenz's presbyopia therapy hits main goal in late-stage Chinese study - FirstWord Pharma

LENZ - LENZ THERAPEUTICS INC Latest Stock News & Market Updates - Stock Titan

 Graphite Bio hands Nasdaq spot to presbyopia biotech Lenz Therapeutics as PhIII readouts loom 

A phenomenal day for LENZ Therapeutics in New York, where we hosted a standout Commercial Day at Nasdaq, showcasing the commercial readiness of LNZ100, our potential best-in-class solution in development for presbyopia.

The event featured powerful first-hand insights from both patients and eye care professionals who participated in our Phase 3 clinical trial — bringing real-world impact to life.

We also shared an exciting preview of our commercial strategy and were thrilled to sit down with special guest Tiffani Thiessen, who brought her own voice to the conversation around presbyopia awareness.

We are energized by the overwhelmingly positive feedback. Thank you to everyone who joined us and to the broader LENZ community for your continued support.

#NASDAQ #Presbyopia #EyeCare #TiffaniThiessen

LENZ Therapeutics Finds $83.5M In Series B - socalTech.com

First-Ever Presbyopia Eye Drop Treatment: LENZ Therapeutics Reveals Latest Progress at BofA Conference - Stock Titan

Walter Whitley, OD looks forward to a new solution for presbyopia that will target the iris sphincter. 

"I’m excited about the future of presbyopia, not only for my patients, but for myself. A solution that selectively targets the iris sphincter to improve near vision is something I’m interested in trying, and it’ll be something my patients welcome too."

LENZ Therapeutics welcomes Joseph B. as Regional Sales Director, East Coast. Joseph comes to LENZ with over 10 years of experience rebuilding and leading high performing teams in multiple specialties. Joseph has extensive experience in eye care from his time at Aerie and Alcon. Joseph also brings a diverse business background to LENZ, including CPG sales, Trade Marketing, Retail Sales Management, and multiple Leadership Certifications. His vast experience in Sales Leadership has helped Joe develop an award winning and successful track record over his career including several President Club Awards. These skills will make Joe a key player as we drive towards commercial readiness.

Join us in welcoming Joe to the team!

 We Think LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Drive Business Growth 

 Lenz Therapeutics' Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape - TipRanks.com 

We are hiring! LENZ Therapeutics is searching for a Supply Chain Logistics Coordinator. 

This position will support the commercialization of LNZ100 at LENZ. This critical role will focus on coordinating international and domestic shipments and ensuring timely delivery of materials and finished goods through our external manufacturing and warehousing partners. 

Read the full description and click the link to apply: https://lnkd.in/g3pkQfTv 


LENZ Therapeutics welcomes Sam Wilson, CPA as Director, Corporate Controller.

Sam brings over 20 years of accounting and finance experience, including the last 15 years in healthcare technology and life sciences. 
 
Across multiple public, high-growth companies, Sam has built modern finance organizations, enhanced internal controls, and aligned financial operations with commercial objectives. He is passionate about building world-class finance teams and fostering a culture of integrity, accountability, and collaboration.

Join us in welcoming Sam to the team!

LENZ Therapeutics' LNZ100 Hits FDA Milestone, Reports 74% Success in Phase 3 Trial - StockTitan

 Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study 

Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth - Simply Wall St

 LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 

 Shareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeutics 

LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia - Business Wire

Piper Sandler raises LENZ Therapeutics stock to Overweight - Investing.com

LENZ Therapeutics welcomes Mansi Parikh, OD as a Medical Science Liaison in the Mid-South. 

Mansi earned her Doctor of Optometry from the New England College of Optometry and spent six years owning and operating multiple subleased clinics across the greater Atlanta area. Her interest in innovation led her to contribute to human factors research, where she applied clinical insights to improve the safety and usability of wearable devices. Most recently, she served as a Clinical Research Optometrist where she served as an investigator for contact lens clinical trials. 

 
Join us in welcoming Mansi to the team!

 LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights 

 Lenz Therapeutics reports Q1 EPS ($3.53), consensus (84c) 

Citi ups PT on LENZ Therapeutics on eye-drop approval confidence - TradingView

 Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress 

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress - Business Wire

LENZ Therapeutics Hosts Commercial Day for LNZ100 - TipRanks

LENZ Therapeutics Positioned for Success with LNZ100 Ahead of 2025 PDUFA Date - TipRanks

LENZ Therapeutics Secures FDA Decision Date with $209M War Chest for Presbyopia Drug Launch - Stock Titan

LENZ Therapeutics Announces Participation in BofA Securities 2025 Health Care Conference - Nasdaq

We are hiring! LENZ Therapeutics is searching for a Director, Regulatory CMC. 

This role will support the development and successful performance of the CMC regulatory strategy for LENZ Therapeutics. This position is based in San Diego, CA and reports to the VP, Regulatory and Clinical Operations.

Read the full description and click the link to apply: https://lnkd.in/g9UzGBEB 

Join LENZ Therapeutics at American Society of Cataract and Refractive Surgery (ASCRS) this week.

Stop by booth #1359 to learn more about the future of presbyopia solutions.

LENZ Therapeutics Debuts With $47 Million Series A Financing - Business Wire

Taiwan's Lotus Pharma inks $125 M deal with LENZ Therapeutics to commercialise presbyopia treatment - BioSpectrum Asia

LENZ Therapeutics Stock Is Attractive Before PDUFA (NASDAQ:LENZ) - Seeking Alpha

Join LENZ Therapeutics at American Optometric Association this week.

Stop by booth #1207 to learn more about the future of presbyopia solutions.

 TD Cowen Upgrades LENZ Therapeutics Inc (LENZ) to Buy 

LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq

 LENZ Therapeutics to Participate in Upcoming Investor Conferences 

Lenz presbyopia drop meets endpoints in near vision improvement in phase 3 trials - Healio

Lenz Therapeutics, Lotus enter license, commercialization agreement for LNZ100 - TipRanks

 Lenz Therapeutics' eye drop helps improve vision in late-stage study 

LENZ Therapeutics

Business:

About: